The SURMOUNT-5 trial, published in The New England Journal of Medicine , directly compared tirzepatide to semaglutide and found tirzepatide produced 47% greater relative weight loss at 72 weeks, 20.2% of body weight versus 13.7%
however, children are not miniature adults and as newer formulations emerge, it cannot be assumed that pharmacokinetics or adverse effects in adults are the same in children or adolescents [Reference Verscheijden, Koenderink, Johnson, de Wildt and Russel22]
10.1530/EC-19-0268 62
CPT code 75561( Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences ) to 5572 (Level 2 Imaging ( with Contrast) with a proposed payment of $358.35 based on a geometric mean cost of around $459 and 29,162 single frequency claims used for ratesetting
This lets researchers use the same reconstituted peptide vial across a sequence of experimental timepoints standard practice for multi-day in-vitro work